Cargando…

Augmented expression of cardiac ankyrin repeat protein is induced by pemetrexed and a possible marker for the pemetrexed resistance in mesothelioma cells

BACKGROUND: Pemetrexed (PEM) is an anti-cancer agent targeting DNA and RNA synthesis, and clinically in use for mesothelioma and non-small cell lung carcinoma. A mechanism of resistance to PEM is associated with elevated activities of several enzymes involved in nucleic acid metabolism. METHODS: We...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qin, Yiyang, Sekine, Ikuo, Fan, Mengmeng, Takiguchi, Yuichi, Tada, Yuji, Shingyoji, Masato, Hanazono, Michiko, Yamaguchi, Naoto, Tagawa, Masatoshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Primary Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5725641/ https://www.ncbi.nlm.nih.gov/pubmed/29238267 http://dx.doi.org/10.1186/s12935-017-0493-8

Ejemplares similares

AMPK activation induced in pemetrexed‐treated cells is associated with development of drug resistance independently of target enzyme expression
por: Qin, Yiyang, et al.
Publicado: (2019)

Interferon-β Produces Synergistic Combinatory Anti-Tumor Effects with Cisplatin or Pemetrexed on Mesothelioma Cells
por: Li, Quanhai, et al.
Publicado: (2013)

An intrapleural administration of zoledronic acid for inoperable malignant mesothelioma patients: a phase I clinical study protocol
por: Tada, Yuji, et al.
Publicado: (2016)

Combination of a third generation bisphosphonate and replication-competent adenoviruses augments the cytotoxicity on mesothelioma
por: Jiang, Yuanyuan, et al.
Publicado: (2016)

An MDM2 inhibitor achieves synergistic cytotoxic effects with adenoviruses lacking E1B55kDa gene on mesothelioma with the wild-type p53 through augmenting NFI expression
por: Nguyen, Thao Thi Thanh, et al.
Publicado: (2021)

An image cytometric technique is a concise method to detect adenoviruses and host cell proteins and to monitor the infection and cellular responses induced
por: Morinaga, Takao, et al.
Publicado: (2017)

A clinical protocol to inhibit the HGF/c-Met pathway for malignant mesothelioma with an intrapleural injection of adenoviruses expressing the NK4 gene
por: Tada, Yuji, et al.
Publicado: (2015)

Metformin produces growth inhibitory effects in combination with nutlin-3a on malignant mesothelioma through a cross-talk between mTOR and p53 pathways
por: Shimazu, Kengo, et al.
Publicado: (2017)

Zoledronic Acid Produces Combinatory Anti-Tumor Effects with Cisplatin on Mesothelioma by Increasing p53 Expression Levels
por: Okamoto, Shinya, et al.
Publicado: (2013)

Review of pemetrexed in combination with cisplatin for the treatment of malignant pleural mesothelioma
por: Goudar, Ranjit K
Publicado: (2008)

Bevacizumab plus cisplatin/pemetrexed then bevacizumab alone for unresectable malignant pleural mesothelioma: A Japanese safety study
por: Nakano, Takashi, et al.
Publicado: (2020)

Human drug efflux transporter ABCC5 confers acquired resistance to pemetrexed in breast cancer
por: Chen, Jihui, et al.
Publicado: (2021)

Re-challenge with pemetrexed in advanced mesothelioma: a multi-institutional experience
por: Bearz, Alessandra, et al.
Publicado: (2012)

Interplay of non-coding RNAs and approved antimetabolites such as gemcitabine and pemetrexed in mesothelioma
por: Biersack, Bernhard
Publicado: (2018)

Dasatinib modulates sensitivity to pemetrexed in malignant pleural mesothelioma cell lines
por: Monica, Valentina, et al.
Publicado: (2016)

Successful desensitization of pemetrexed-induced anaphylaxis in a patient with malignant mesothelioma
por: Youk, Jeonghwan, et al.
Publicado: (2017)

Upregulation of Thymidylate Synthase Induces Pemetrexed Resistance in Malignant Pleural Mesothelioma
por: Sato, Yuzo, et al.
Publicado: (2021)

Pemetrexed induced pneumonitis
por: Dhakal, Binod, et al.
Publicado: (2011)

Prediction of the VeriStrat test in first-line therapy of pemetrexed-based regimens for advanced lung adenocarcinoma patients
por: Jia, Bo, et al.
Publicado: (2020)

Molecular Resistance Fingerprint of Pemetrexed and Platinum in a Long-Term Survivor of Mesothelioma
por: Røe, Oluf Dimitri, et al.
Publicado: (2012)

Polymorphisms in folate pathway and pemetrexed treatment outcome in patients with malignant pleural mesothelioma
por: Goricar, Katja, et al.
Publicado: (2014)

A Case Report of Primary Pericardial Malignant Mesothelioma Treated with Pemetrexed and Cisplatin
por: Kim, Jung Sun, et al.
Publicado: (2017)

Pemetrexed-loaded nanoparticles targeted to malignant pleural mesothelioma cells: an in vitro study
por: Cova, Emanuela, et al.
Publicado: (2019)

Efficacy and safety of pemetrexed and nedaplatin followed by pemetrexed maintenance therapy in advanced lung adenocarcinoma
por: Lin, Zhong, et al.
Publicado: (2017)

Pemetrexed for epithelioid haemangioendothelioma of the pleura
por: Kanemura, Shingo, et al.
Publicado: (2016)

Effect of renal function on pemetrexed-induced haematotoxicity
por: Ando, Yosuke, et al.
Publicado: (2016)

Schedule-dependent increased efficiency of pemetrexed-ionizing radiation combination therapy elicits a differential DNA damage response in lung cancer cells
por: Dorn, Patrick, et al.
Publicado: (2016)

Cisplatin-resistant A549 non-small cell lung cancer cells can be identified by increased mitochondrial mass and are sensitive to pemetrexed treatment
por: Gao, Yanyun, et al.
Publicado: (2019)

Adjuvant Bidirectional Chemotherapy with Intraperitoneal Pemetrexed Combined with Intravenous Cisplatin for Diffuse Malignant Peritoneal Mesothelioma
por: Bijelic, Lana, et al.
Publicado: (2012)

Synergistic anti-tumor effect of bullfrog sialic acid-binding lectin and pemetrexed in malignant mesothelioma
por: Satoh, Toshiyuki, et al.
Publicado: (2017)

In Vitro Characterization of Cisplatin and Pemetrexed Effects in Malignant Pleural Mesothelioma 3D Culture Phenotypes
por: Papazoglou, Eleftherios D., et al.
Publicado: (2019)

Antagonist of Growth Hormone-Releasing Hormone Potentiates the Antitumor Effect of Pemetrexed and Cisplatin in Pleural Mesothelioma
por: Gesmundo, Iacopo, et al.
Publicado: (2022)

Zoledronic acid induces apoptosis and S-phase arrest in mesothelioma through inhibiting Rab family proteins and topoisomerase II actions
por: Okamoto, S, et al.
Publicado: (2014)

Eyelid and feet edema induced by pemetrexed
por: Kastalli, Sarrah, et al.
Publicado: (2016)

Nephrotoxicity in a Patient Treated with Pemetrexed
por: Zajjari, Y., et al.
Publicado: (2017)

Pemetrexed Induced Life-threatening Anaphylaxis
por: Rajasurya, Venkat, et al.
Publicado: (2019)

Edema of the face and extremities secondary to pemetrexed
por: Doyle, Thomas, et al.
Publicado: (2023)

New Polymorphic Forms of Pemetrexed Diacid and Their Use for the Preparation of Pharmaceutically Pure Amorphous and Hemipentahydrate Forms of Pemetrexed Disodium
por: Michalak, Olga, et al.
Publicado: (2015)

The role of folate receptor alpha (FRα) in the response of malignant pleural mesothelioma to pemetrexed-containing chemotherapy
por: Nutt, J E, et al.
Publicado: (2010)

Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma
por: Ceresoli, G L, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_44lc6nfvqhc02vkbfc4h4anaut